Dose and outcomes in primary immunodeficiency disorders
2014; Oxford University Press; Volume: 178; Linguagem: Inglês
10.1111/cei.12492
ISSN1365-2249
Autores Tópico(s)Cystic Fibrosis Research Advances
ResumoClinical & Experimental ImmunologyVolume 178, Issue S1 p. 7-9 ImmunodeficienciesFree Access Dose and outcomes in primary immunodeficiency disorders V. R. Bonagura, Corresponding Author V. R. Bonagura Hofstra North Shore-LIJ School of Medicine, Steven and Alexandra Cohen Children's Medical Center of New York, New York, NY, USA Correspondence: V. R. Bonagura. E-mail: vbonagura@nshs.eduSearch for more papers by this author V. R. Bonagura, Corresponding Author V. R. Bonagura Hofstra North Shore-LIJ School of Medicine, Steven and Alexandra Cohen Children's Medical Center of New York, New York, NY, USA Correspondence: V. R. Bonagura. E-mail: vbonagura@nshs.eduSearch for more papers by this author First published: 29 December 2014 https://doi.org/10.1111/cei.12492Citations: 7AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Kindle G, Warnatz K, Paschenko O et al. Differences in clinical outcome in patients with common variable immunodeficiency treated with Ig replacement therapy: results from the ESID database. J Allergy Clin Immunol 2011; 127: AB13. 2Berger M. Subcutaneous IgG therapy in immune deficiency diseases. Clin Focus Primary Immune Defic 2008; 13: 1– 12. 3Misbah S, Sturzenegger MH, Borte M et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol 2009; 158 (Suppl. 1): 51– 59. 4Wasserman RL, Melamed I, Stein MR et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol 2012; 130: 951– 957. e11. 5Nicolay U, Kiessling P, Berger M et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 2006; 26: 65– 72. 6Hernandez-Trujillo HS, Chapel H, Lo Re V 3rd et al. Comparison of American and European practices in the management of patients with primary immunodeficiencies. Clin Exp Immunol 2012; 169: 57– 69. 7Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol 2010; 137: 21– 30. 8Orange JS, Belohradsky BH, Berger M et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol 2012; 169: 172– 181. 9Lau YL, Jones BM, Ng KW, Yeung CY. Percentile ranges for serum IgG subclass concentrations in healthy Chinese children. Clin Exp Immunol 1993; 91: 337– 341. 10Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008; 122: 210– 212. 11Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010; 125: 1354– 1360; e4. 12Quinti I, Soresina A, Guerra A et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol 2011; 31: 315– 322. 13Notarangelo LD, Plebani A, Mazzolari E, Soresina A, Bondioni MP. Genetic causes of bronchiectasis: primary immune deficiencies and the lung. Respiration 2007; 74: 264– 275. 14de Gracia J, Vendrell M, Alvarez A et al. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol 2004; 4: 745– 753. 15Chen Y, Stirling RG, Paul E, Hore-Lacy F, Thompson BR, Douglass JA. Longitudinal decline in lung function in patients with primary immunoglobulin deficiencies. J Allergy Clin Immunol 2011; 127: 1414– 1417. Citing Literature Volume178, IssueS1Special Issue: Proceedings from the 7th International Immunoglobulin Conference, Interlaken, Switzerland, April 2014. Guest Editors: Stephen Jolles, Stanley C. Jordan, Jordan S. Orange and Ivo N. van Schaik. This supplement has been supported by an educational grant from CSL Behring, financial support from Wiley and Clinical and Experimental Immunology and the scientific programme at the Conference was endorsed by the British Society of Immunology.December 2014Pages 7-9 ReferencesRelatedInformation
Referência(s)